Cargando…

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

BACKGROUND: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic strategy in cutaneous melanoma. Here, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chiao-En, Esfandiari, Arman, Ho, Yi-Hsuan, Wang, Nan, Mahdi, Ahmed Khairallah, Aptullahoglu, Erhan, Lovat, Penny, Lunec, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830592/ https://www.ncbi.nlm.nih.gov/pubmed/29235570 http://dx.doi.org/10.1038/bjc.2017.433

Ejemplares similares

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
por: Wu, Chiao-En, et al.
Publicado: (2019)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53(WT) Uterine Leiomyosarcoma
por: Chamberlain, Victoria, et al.
Publicado: (2021)

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
por: Canner, J A, et al.
Publicado: (2009)

p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
por: Aptullahoglu, Erhan, et al.
Publicado: (2023)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells
por: Wu, Chiao-En, et al.
Publicado: (2021)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
por: Ciardullo, Carmela, et al.
Publicado: (2019)

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
por: Aptullahoglu, Erhan, et al.
Publicado: (2023)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57
por: Corazzari, M, et al.
Publicado: (2007)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation
por: Lopergolo, A, et al.
Publicado: (2009)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
por: Sorriento, D, et al.
Publicado: (2015)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oa9fmmgrgtpa6oshq93ua97ndu